Business Context and Reporting Period
Company: Integra LifeSciences Holdings Corp (IART)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Integra is a global medical technology company operating in two segments: Codman Specialty Surgical (CSS), comprising neurosurgery, neurocritical care, and ENT (approx. 70% of revenue); and Tissue Technologies (TT), focusing on wound reconstruction and private label (approx. 30% of revenue). The company is headquartered in Princeton, New Jersey.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $1,635.2 million | $1,610.5 million |
| Gross Margin | $831.6 million (50.9%) | $882.1 million (54.8%) |
| Operating Loss | $(493.4) million | $28.4 million (Income) |
| Net Loss | $(516.5) million | $(6.9) million |
| Diluted EPS | $(6.74) | $(0.09) |
| Operating Cash Flow | $50.4 million | $129.4 million |
| Total Debt (External) | ~$1.9 billion | ~$1.8 billion |
| Cash & Equivalents | $235.0 million | $246.4 million |
| Working Capital | $703.6 million | $159.6 million |
Material Changes vs. Prior Period
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $511.4 million in Q2 2025. This was driven by a decrease in stock price, tariff-related economic uncertainty, and quality/operational issues. The charge was allocated across Tissue Technologies ($123.3M), Neurosurgery ($249.0M), and Instruments/ENT ($139.1M).
- Revenue Growth: Total revenue increased 1.5% to $1.635 billion. CSS revenue grew 5.0% (driven by the Acclarent acquisition), while TT revenue declined 6.9% due to quality issues with MediHoney and lower private label sales.
- Margin Compression: Gross margin percentage decreased from 54.8% to 50.9% due to quality/operational issues, higher manufacturing costs, and tariff impacts ($19.9M incurred in 2025).
- Debt Refinancing: The company repaid $575.0 million in Convertible Senior Notes at maturity in August 2025, funding the repayment via its Senior Credit Facility.
Guidance, Outlook, and Risks
- Regulatory & Quality (FDA Matters): The company received a Warning Letter in December 2024 regarding quality system issues at three facilities (Mansfield, Plainsboro, Princeton). A voluntary recall of MediHoney products occurred in 2025 due to packaging failures; a definitive relaunch date remains unknown. The company is executing a Compliance Master Plan (CMP) and transitioning manufacturing of PriMatrix and SurgiMend to a new Braintree, MA facility expected to be operational in 2026.
- Product Pipeline: The company anticipates PMA approval for SurgiMend and DuraSorb in 2026, contingent on the operationalization of the Braintree facility.
- Tariff & Macroeconomic Risks: Significant uncertainty exists regarding U.S. tariffs. In February 2026, the Supreme Court invalidated the IEEPA tariff program, but a new global 10% tariff was announced. The company incurred $19.9M in tariff costs in 2025.
- Restructuring: A new restructuring initiative approved in Q4 2025 is expected to cost approximately $12.6 million through the end of 2026 to improve supply chain stability.
- Legal Proceedings: Pending arbitration regarding ACell earnout consideration and ongoing securities class action litigation related to FDA quality issues.
Investor Verification Checklist
- Goodwill Impairment Assumptions: Verify the sensitivity of the $511.4M impairment charge to changes in revenue growth rates and discount rates, given the volatility in the tariff environment.
- FDA Remediation Timeline: Confirm the status of the Compliance Master Plan (CMP) and the specific timeline for the Braintree facility operationalization, as this is critical for the relaunch of key TT products (SurgiMend, PriMatrix).
- MediHoney Relaunch: Assess the impact of the ongoing MediHoney recall on TT segment revenue and the timeline for product availability.
- Tariff Exposure: Evaluate the company's ability to pass on tariff costs to customers or mitigate supply chain disruptions, particularly for products manufactured in the U.S. and sold in China/EU.
- Debt Covenants: Review the Consolidated Total Leverage Ratio (4.50x at year-end) against the covenant requirement (5.00x) and the impact of the June 2025 amendment on future borrowing capacity.